Turnstone Biologics Corp. Common Stock
Turnstone Biologics Corp. operates as a biotechnology company. The company was founded in 2014 and is headquartered in San Diego, California. As of August 11, 2025, Turnstone Biologics Corp. operates as a subsidiary of XOMA Royalty Corporation.
Turnstone Biologics Corp. Common Stock (TSBX) - Net Assets
Latest net assets as of June 2025: $14.76 Million USD
Based on the latest financial reports, Turnstone Biologics Corp. Common Stock (TSBX) has net assets worth $14.76 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($21.11 Million) and total liabilities ($6.34 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $14.76 Million |
| % of Total Assets | 69.94% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Turnstone Biologics Corp. Common Stock - Net Assets Trend (2021–2024)
This chart illustrates how Turnstone Biologics Corp. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Turnstone Biologics Corp. Common Stock (2021–2024)
The table below shows the annual net assets of Turnstone Biologics Corp. Common Stock from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $31.47 Million | -68.11% |
| 2023-12-31 | $98.67 Million | +197.24% |
| 2022-12-31 | $-101.47 Million | -23.97% |
| 2021-12-31 | $-81.85 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Turnstone Biologics Corp. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15687100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $23.00K | 0.07% |
| Other Comprehensive Income | $-202.00K | -0.64% |
| Other Components | $279.24 Million | 887.41% |
| Total Equity | $31.47 Million | 100.00% |
Turnstone Biologics Corp. Common Stock Competitors by Market Cap
The table below lists competitors of Turnstone Biologics Corp. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VVC Exploration Corporation
OTCQB:VVCVF
|
$5.01 Million |
|
Wolfden Resources Corporation
PINK:WLFFF
|
$5.01 Million |
|
Sunshine Biopharma Inc
NASDAQ:SBFM
|
$5.01 Million |
|
China Oceanwide Holdings Limited
F:HRH
|
$5.01 Million |
|
Sports Entertainment Group Ltd
AU:SEG
|
$5.01 Million |
|
Hitek Global Inc.
F:4JX
|
$5.00 Million |
|
Da Lue International Holding Co Ltd
TWO:4804
|
$5.00 Million |
|
Solid Automotive Bhd
KLSE:5242
|
$5.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Turnstone Biologics Corp. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 98,667,000 to 31,467,000, a change of -67,200,000 (-68.1%).
- Net loss of 70,837,000 reduced equity.
- Other comprehensive income decreased equity by 83,000.
- Other factors increased equity by 3,720,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-70.84 Million | -225.12% |
| Other Comprehensive Income | $-83.00K | -0.26% |
| Other Changes | $3.72 Million | +11.82% |
| Total Change | $- | -68.11% |
Book Value vs Market Value Analysis
This analysis compares Turnstone Biologics Corp. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.26x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $-3.69 | $0.36 | x |
| 2022-12-31 | $-4.57 | $0.36 | x |
| 2023-12-31 | $4.88 | $0.36 | x |
| 2024-12-31 | $1.37 | $0.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Turnstone Biologics Corp. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -225.12%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.28x
- Recent ROE (-225.12%) is below the historical average (-70.27%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 32.84% | 0.54x | 0.00x | $41.45 Million |
| 2022 | 0.00% | -42.07% | 0.64x | 0.00x | $-20.69 Million |
| 2023 | -55.95% | -285.92% | 0.17x | 1.14x | $-65.07 Million |
| 2024 | -225.12% | 0.00% | 0.00x | 1.28x | $-73.98 Million |
Industry Comparison
This section compares Turnstone Biologics Corp. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Turnstone Biologics Corp. Common Stock (TSBX) | $14.76 Million | 0.00% | 0.43x | $5.01 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |